AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26011507 — intervention group
Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 15
Study 23503379 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic therapy combined with traditional treatment (conservative means) in 39 patients.
Number of subjects: 134
Study 23503379 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic therapy combined with reconstructive vascular operations in 35 patients.
Number of subjects: 134
Study 23503379 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatment (control group) in 60 patients.
Number of subjects: 134
Study 22375408 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory exercises increases Chinese medicine
Number of subjects: 216
Study 22375408 — intervention group
Group type: COMPARATOR
Intervention: Respiratory exercises increases placebo
Number of subjects: 216
Study 18823290 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-38488502 (0.42 mg kg(‐1) i.v. infusion)
Number of subjects: 23
Study 18823290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 18823290 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-38488502
Number of subjects: 23
Study 17297424 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy strategies (including gene directed enzyme/pro-drug therapy, inhibition of oncogenes, restoration of tumor-suppressor genes, immunotherapy, anti-angiogenesis, and virotherapy)
Number of subjects: 0
Study 15284373 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.00 g protein/(kg. d)
Number of subjects: 50
Study 15284373 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 g protein/(kg. d)
Number of subjects: 50
Study 15284373 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50 g protein/(kg. d)
Number of subjects: 50
Study 15284373 — intervention group
Group type: COMPARATOR
Intervention: 1.20 g protein/(kg. d) for 2 wk (HPro)
Number of subjects: 50
Study 15284373 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 g protein/(kg. d) for 1 wk and then 0.50 g protein/(kg. d) for a 2nd week (IPro)
Number of subjects: 50
Study 11510711 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised analysis of fetal heart rate patterns
Number of subjects: 679
Study 9663533 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrifugal pump
Number of subjects: 42
Study 9663533 — intervention group
Group type: COMPARATOR
Intervention: Roller pump
Number of subjects: 42
Study 7918934 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (3,000,000 units three times per week for at least six months)
Number of subjects: 9
Study 7918934 — intervention group
Group type: COMPARATOR
Intervention: Pre-treatment
Number of subjects: 9
Study 2701186 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-influenza vaccine
Number of subjects: 217
Study 2701186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study 4918459 — intervention group
Group type: EXPERIMENTAL
Intervention: CIBA 34,647‐Ba (gamma aminobutyric acid derivative)
Number of subjects: 0
Study 4918459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 4918459 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 0
Study 31197991 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative traction
Number of subjects: 120
Study 31197991 — intervention group
Group type: COMPARATOR
Intervention: Non-preoperative traction
Number of subjects: 120
Study 28314555 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacain injection (L group)
Number of subjects: 96
Study 28314555 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacain and magnesium sulfate injection (LM group)
Number of subjects: 96
Study 28314555 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular saline injection (control group)
Number of subjects: 96
Study 26165259 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion through an On Q continuous infusion pump (On Q group)
Number of subjects: 50
Study 26165259 — intervention group
Group type: COMPARATOR
Intervention: Single shot popliteal sciatic nerve block (SSB group)
Number of subjects: 50
Study 26165259 — intervention group
Group type: EXPERIMENTAL
Intervention: On Q group
Number of subjects: 50
Study 23257347 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimosiamose (10 mg) inhaled twice daily for 28 days
Number of subjects: 77
Study 23257347 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhaled twice daily for 28 days
Number of subjects: 77
Study 21939965 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory signal with certain visual information
Number of subjects: 0
Study 21939965 — intervention group
Group type: COMPARATOR
Intervention: Ambiguous pronunciation attributed to an external source
Number of subjects: 0
Study 18306343 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based treatment (FBT-BN)
Number of subjects: 80
Study 18306343 — intervention group
Group type: COMPARATOR
Intervention: Individual supportive psychotherapy (SPT)
Number of subjects: 80
Study 16763797 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium dobesilate (CaD) 2 g daily for 24 months
Number of subjects: 194
Study 16763797 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium dobesilate (CaD)
Number of subjects: 194
Study 16763797 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 194
Study 15886245 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin (100 mg, twice daily)
Number of subjects: 20
Study 15886245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12970658 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid fixation (n = 78)
Number of subjects: 127
Study 12970658 — intervention group
Group type: COMPARATOR
Intervention: Wire fixation (n = 49)
Number of subjects: 127
Study 12970658 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid fixation with genioplasty (n = 35)
Number of subjects: 127
Study 12970658 — intervention group
Group type: COMPARATOR
Intervention: Wire fixation with genioplasty (n = 24)
Number of subjects: 127
Study 10081536 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose 10%, 3 ml.kg‐1.h‐1 (300 mg.kg‐1.h‐1)
Number of subjects: 18
Study 10081536 — intervention group
Group type: COMPARATOR
Intervention: Glucose-free fluid regime
Number of subjects: 18
Study 7593729 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide 150 mg twice daily
Number of subjects: 270
Study 7593729 — intervention group
Group type: COMPARATOR
Intervention: Moclobemide 300 mg three times daily
Number of subjects: 270
Study 7593729 — intervention group
Group type: COMPARATOR
Intervention: Moclobemide 450 mg three times daily
Number of subjects: 270
Study 7593729 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 270
Study 2174312 — intervention group
Group type: EXPERIMENTAL
Intervention: Infused branched-chain amino acids
Number of subjects: 20
Study 2174312 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 20
Study 7389384 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg sustained-release amitriptyline (doubled after 1 week)
Number of subjects: 40
Study 7389384 — intervention group
Group type: COMPARATOR
Intervention: 75 mg maprotiline (doubled after 1 week)
Number of subjects: 40
Study 30591028 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaratumab (20 mg/kg, IV infusion) plus liposomal doxorubicin (40 mg/m2, IV infusion) every 4 weeks
Number of subjects: 123
Study 30591028 — intervention group
Group type: COMPARATOR
Intervention: Liposomal doxorubicin (40 mg/m2, IV infusion) every 4 weeks
Number of subjects: 123
Study 30591028 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaratumab+liposomal doxorubicin in platinum-refractory subgroup (n=15)
Number of subjects: 123
Study 30591028 — intervention group
Group type: COMPARATOR
Intervention: Liposomal doxorubicin in platinum-refractory subgroup (n=16)
Number of subjects: 123
Study 30591028 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaratumab+liposomal doxorubicin
Number of subjects: 123
Study 30591028 — intervention group
Group type: COMPARATOR
Intervention: Liposomal doxorubicin
Number of subjects: 123
Study 27013576 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Postural Re-education (GPR)
Number of subjects: 94
Study 27013576 — intervention group
Group type: COMPARATOR
Intervention: Manual Therapy (MT)
Number of subjects: 94
Study 24104699 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates exercise (1-hour lesson, 5 lessons per week for 6 months)
Number of subjects: 60
Study 24104699 — intervention group
Group type: COMPARATOR
Intervention: Inactivity control group (normal daily activities)
Number of subjects: 60
Study 22449319 — intervention group
Group type: COMPARATOR
Intervention: Intensive medical therapy alone
Number of subjects: 150
Study 22449319 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy plus Roux‐en‐Y gastric bypass
Number of subjects: 150
Study 22449319 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy plus sleeve gastrectomy
Number of subjects: 150
Study 22449319 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 150
Study 21094362 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone, enalapril, and a β blocker (Group A)
Number of subjects: 164
Study 21094362 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone and a β blocker (Group B)
Number of subjects: 164
Study 21094362 — intervention group
Group type: COMPARATOR
Intervention: Enalapril plus a β blocker (Group C)
Number of subjects: 164
Study 21094362 — intervention group
Group type: COMPARATOR
Intervention: β blocker alone (Group D)
Number of subjects: 164
Study 17719849 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational studies
Number of subjects: 0
Study 17719849 — intervention group
Group type: COMPARATOR
Intervention: Randomised control trials (RCTs)
Number of subjects: 0
Study 17719849 — intervention group
Group type: COMPARATOR
Intervention: Ethics committee approval
Number of subjects: 0
Study 17004410 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO2) at 1.75 atm abs (n=57)
Number of subjects: 111
Study 17004410 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving air at 1.3 atm abs (n=54)
Number of subjects: 111
Study 14522286 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspheric IOL (Tecnis Z‐9000)
Number of subjects: 221
Study 14522286 — intervention group
Group type: COMPARATOR
Intervention: Acrylic IOL (AcrySof SA60AT)
Number of subjects: 221
Study 14522286 — intervention group
Group type: COMPARATOR
Intervention: Silicone IOL (AA4207VF)
Number of subjects: 221
Study 10907671 — intervention group
Group type: COMPARATOR
Intervention: Grapefruit juice (600 ml/day) in healthy volunteers
Number of subjects: 19
Study 10907671 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice (600 ml/day) in patients with anxiety disorders
Number of subjects: 19
Study 8615108 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous passive motion (CPM)
Number of subjects: 68
Study 8615108 — intervention group
Group type: COMPARATOR
Intervention: Active physical therapy (APT)
Number of subjects: 68
Study 1418829 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic magnesium administration (15.8 mmol/day)
Number of subjects: 42
Study 1418829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 6140935 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg
Number of subjects: 12
Study 6140935 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg
Number of subjects: 12
Study 6140935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29962492 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-wide intervention for frailty prevention
Number of subjects: 15500
Study 29962492 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 15500
Study 28787224 — intervention group
Group type: EXPERIMENTAL
Intervention: youth-physical activity toward health intervention
Number of subjects: 482
Study 27207107 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (1250 mg/m² i.v., days 1 and 8) and cisplatin (75 mg/m² i.v., day 1) plus necitumumab (800 mg i.v., days 1 and 8)
Number of subjects: 982
Study 27207107 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine (1250 mg/m² i.v., days 1 and 8) and cisplatin (75 mg/m² i.v., day 1) alone
Number of subjects: 982
Study 27207107 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine-cisplatin plus necitumumab
Number of subjects: 982
Study 24972789 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 100
Study 24972789 — intervention group
Group type: COMPARATOR
Intervention: Spinal anaesthesia
Number of subjects: 100
Study 22527887 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide 50 μg sc qd for 14 days
Number of subjects: 33
Study 22527887 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide 200 μg sc qd for 14 days
Number of subjects: 33
Study 22527887 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide 600 μg sc qd for 14 days
Number of subjects: 33
Study 22527887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 20861810 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of radiation therapy
Number of subjects: 0
Study 20861810 — intervention group
Group type: EXPERIMENTAL
Intervention: More conformal radiation therapy techniques (intensity‐modulated radiation therapy, proton therapy, stereotactic body radiotherapy, brachytherapy)
Number of subjects: 0
Study 18926160 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 746
Study 18926160 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 746
Study 18926160 — intervention group
Group type: EXPERIMENTAL
Intervention: Major bleeding
Number of subjects: 746
Study 18926160 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ECG monitoring
Number of subjects: 746
Study 16299240 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly oral aminopterin, 2 mg/m2, given in two doses 12 hours apart.
Number of subjects: 46
Study 16299240 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminopterin (in vitro)
Number of subjects: 46
Study 12623851 — intervention group
Group type: EXPERIMENTAL
Intervention: RIT with 100 mg alemtuzumab in vivo over 5 days
Number of subjects: 2
Study 12623851 — intervention group
Group type: COMPARATOR
Intervention: Myeloablative allografts with 20 mg alemtuzumab added in vitro to the stem cells prior to return
Number of subjects: 2
Study 10599980 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard meal producing lower postprandial hyperglycemia
Number of subjects: 10
Study 10599980 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard meal producing higher postprandial hyperglycemia
Number of subjects: 10
Study 7826271 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe carotid artery stenosis
Number of subjects: 2394
Study 7826271 — intervention group
Group type: COMPARATOR
Intervention: Mild carotid artery stenosis
Number of subjects: 2394
Study 7826271 — intervention group
Group type: COMPARATOR
Intervention: History of hypertension
Number of subjects: 2394
Study 7826271 — intervention group
Group type: COMPARATOR
Intervention: History of myocardial infarction
Number of subjects: 2394
Study 7826271 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing age
Number of subjects: 2394
Study 7826271 — intervention group
Group type: EXPERIMENTAL
Intervention: History of stroke
Number of subjects: 2394
Study 2201659 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine, 2 g/day for three months
Number of subjects: 60
Study 2201659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 7042126 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% benzydamine plus tricetol as preservative
Number of subjects: 30
Study 7042126 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% benzydamine alone
Number of subjects: 30
Study 7042126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31657080 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program and multidisciplinary care program
Number of subjects: 0
Study 30222518 — intervention group
Group type: EXPERIMENTAL
Intervention: Online care
Number of subjects: 300
Study 30222518 — intervention group
Group type: COMPARATOR
Intervention: In-person care
Number of subjects: 300
Study 30584292 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow Deep-Breathing Technique (SDBT)
Number of subjects: 30
Study 30584292 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast Deep-Breathing Technique (FDBT)
Number of subjects: 30
Study 26960786 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular therapy of 1 ml Vitamin B12 (2500 mcg) weekly for 6 weeks
Number of subjects: 40
Study 26960786 — intervention group
Group type: COMPARATOR
Intervention: Placebo isotonic saline 01 ml intramuscular
Number of subjects: 40
Study 24316677 — intervention group
Group type: EXPERIMENTAL
Intervention: LINE1 methylation quartiles (Q2-Q4) in male smokers
Number of subjects: 580
Study 24316677 — intervention group
Group type: EXPERIMENTAL
Intervention: LINE1 methylation quartiles (Q2-Q4) in male smokers (ATBC validation)
Number of subjects: 580
Study 24316677 — intervention group
Group type: EXPERIMENTAL
Intervention: LINE1 methylation quartiles (Q2-Q4) pooled analysis of PLCO and ATBC male smokers
Number of subjects: 580
Study 24316677 — intervention group
Group type: COMPARATOR
Intervention: LINE1 methylation quartile (Q1)
Number of subjects: 580
Study 21788032 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral repair in addition to coronary artery bypass grafting
Number of subjects: 0
Study 21788032 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting alone
Number of subjects: 0
Study 19854729 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline heart rate
Number of subjects: 11256
Study 19854729 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired baseline creatinine clearance
Number of subjects: 11256
Study 19854729 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior MI
Number of subjects: 11256
Study 19854729 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial left ventricular ejection fraction <40%
Number of subjects: 11256
Study 19854729 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent cardiovascular events
Number of subjects: 11256
Study 19854729 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation post-MI
Number of subjects: 11256
Study 17963624 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 173
Study 17963624 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 173
Study 16239177 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone treatment
Number of subjects: 107
Study 16239177 — intervention group
Group type: COMPARATOR
Intervention: Vigabatrin
Number of subjects: 107
Study 16239177 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone treatment (no identified underlying aetiology)
Number of subjects: 107
Study 16239177 — intervention group
Group type: COMPARATOR
Intervention: Vigabatrin (no identified underlying aetiology)
Number of subjects: 107
Study 12404749 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple dietary education
Number of subjects: 68
Study 12404749 — intervention group
Group type: COMPARATOR
Intervention: Conventional dietary education
Number of subjects: 68
Study 10489049 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 x 25 mg acetylsalicylic acid (ASA)
Number of subjects: 6602
Study 10489049 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 x 200 mg dipyridamole (DP)
Number of subjects: 6602
Study 10489049 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 50 mg ASA and 400 mg DP
Number of subjects: 6602
Study 10489049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6602
Study 9123900 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 1332
Study 9123900 — intervention group
Group type: EXPERIMENTAL
Intervention: Orimeten
Number of subjects: 1332
Study 9123900 — intervention group
Group type: COMPARATOR
Intervention: Diethyl-stilbestrol
Number of subjects: 1332
Study 1924052 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 100 mg twice daily
Number of subjects: 12
Study 1924052 — intervention group
Group type: COMPARATOR
Intervention: Frusemide 40 mg once daily
Number of subjects: 12
Study 7117676 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release frusemide (twice-daily)
Number of subjects: 26
Study 7117676 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release frusemide (once-daily)
Number of subjects: 26
Study 7117676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 31731368 — intervention group
Group type: EXPERIMENTAL
Intervention: ETV + ADV (0.5 mg + 10 mg per day)
Number of subjects: 100
Study 31731368 — intervention group
Group type: COMPARATOR
Intervention: TDF (300 mg per day)
Number of subjects: 100
Study 28766016 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE with miriplatin
Number of subjects: 257
Study 28766016 — intervention group
Group type: COMPARATOR
Intervention: TACE with epirubicin
Number of subjects: 257
Study 27490918 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/d soy isoflavones
Number of subjects: 70
Study 27490918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 24668328 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil arm (n = 215)
Number of subjects: 650
Study 24668328 — intervention group
Group type: EXPERIMENTAL
Intervention: irinotecan plus cisplatin arm (n = 216)
Number of subjects: 650
Study 24668328 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 arm (n = 219)
Number of subjects: 650
Study 24668328 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk group (0 or 1 risk factor, n = 225)
Number of subjects: 650
Study 24668328 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-risk group (2 or 3 risk factors, n = 368)
Number of subjects: 650
Study 24668328 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk group (all 4 risk factors, n = 57)
Number of subjects: 650
Study 22813645 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate (early) therapy with ART initiated upon enrollment plus HIV primary care
Number of subjects: 1763